Fundraising FoxNeuropro Therapeutics
Yachats, US · North Carolina corporation
Find your way into Neuropro Therapeutics
Sign up to see every warm intro you have to Neuropro Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neuropro Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NeuroPro is developing NPT 2042, a drug candidate targeting epilepsy, with reported efficacy in pharmacology models comparable to NKCC antagonists such as bumetanide and furosemide. The compound has shown plasma exposure across species including humans and no negative safety signals in animals or humans to date.
Founders & leadership
Board
LS
Louis SerafiniBoard director
LC
Luciano CacioppoBoard director
Reported raises · per SEC filings
Form D private placements$5.3M disclosed across 2 rounds · 2016–2023
▶$5.1MraisedApr 2023 · 2 investors · BiotechnologyRule 506(b)
▶$5.1MraisedApr 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daryl W. HochmanExecutive Officer, Director
- Louis SerafiniDirector
- Luciano CacioppoDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Mar 2023
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$215.9KraisedDec 2016 · 4 investors · BiotechnologyRule 506(b)
▶$215.9KraisedDec 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DARYL HOCHMANExecutive Officer, Director
- Offering amount
- $220K
- Amount sold
- $215.9K
- First sale
- Jul 2016
- Incorporated
- Corporation, North Carolina, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Insitroinsitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines. The company serves patients and pharmaceutical development by integrating in vitro lab data with human clinical data to decode biology and unlock transformative treatments.
Monopar TherapeuticsMonopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology and a treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceutical candidates targeting advanced solid tumors (MNPR-101-Zr for imaging, MNPR-101-Lu and MNPR-101-Ac for therapy) and the late-stage Wilson Disease drug ALXN1840.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Companies working in the same space as Neuropro Therapeutics.
Frequently asked questions
- What does Neuropro Therapeutics do?
- NeuroPro is developing NPT 2042, a drug candidate targeting epilepsy, with reported efficacy in pharmacology models comparable to NKCC antagonists such as bumetanide and furosemide. The compound has shown plasma exposure across species including humans and no negative safety signals in animals or humans to date.
- Who founded Neuropro Therapeutics?
- Neuropro Therapeutics was founded by Daryl W. Hochman.
- How much funding has Neuropro Therapeutics raised?
- Neuropro Therapeutics has disclosed $5.3M raised across 2 rounds.
- Where is Neuropro Therapeutics headquartered?
- Neuropro Therapeutics is headquartered in Yachats, US.